ArticleTuberculosis and respiratory diseases2026
Blood Eosinophil Count, Disease Severity, and Exacerbation Risk in Korean Patients with Bronchiectasis: A Retrospective Cohort Study.
Article in Tuberculosis and respiratory diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPeripheral blood eosinophil counts have been associated with bronchiectasis outcomes, but findings remain inconsistent, and their role in acute exacerbations among Korean patients is unclear.
methodsThis study retrospectively evaluated 491 patients with bronchiectasis at a tertiary hospital in Korea between 2014 and 2021. Using a negative binomial regression model adjusted for follow-up duration, we evaluated the association between peripheral eosinophil counts and acute exacerbations in Korean patients with bronchiectasis.
resultsAmong the 491 patients, 190 (38.7%) were categorized into the lower eosinophilic group, 221 (45.0%) into the normal eosinophilic group, and 80 (16.3%) into the higher eosinophilic group. No significant differences were observed across eosinophilic groups in terms of hospitalization within 1 year, bronchiectasis severity index scores, or forced expiratory volume in 1 second (F), age (A), presence of chronic colonization by Pseudomonas aeruginosa (C), radiological extension (number of pulmonary lobes affected) (E), dyspnea (D) (FACED) scores (all p>0.05). In the parsimonious negative binomial regression analysis with false discovery rate (FDR) correction, oral corticosteroid use (incidence rate ratio [IRR], 2.26; 95% confidence interval [CI], 1.46 to 3.52; FDR p=0.001), older age (IRR, 1.03; 95% CI, 1.01 to 1.04; FDR p=0.002), and lower forced expiratory volume in 1 second (FEV1) % predicted (IRR, 0.98; 95% CI, 0.97 to 0.99; FDR p<0.001) were identified as independent risk factors for acute exacerbations.
conclusionThere was no significant association between peripheral blood eosinophil counts and either acute exacerbations or disease severity in Korean patients with bronchiectasis. In contrast, older age, lower lung function (FEV1 % predicted), and the use of oral corticosteroids were identified as independent risk factors for acute exacerbations. These findings underscore the importance of considering region-specific clinical and epidemiological factors in the management of bronchiectasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.